OrbiMed’s Cytek Biosciences CTKB Stock Holding History

OrbiMed’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,923,139	Closed	-$31.4M	–	147
2021 Q4	$31.4M	Hold	1,923,139	–	–	0.4%	66
2021 Q3	$41.2M	Buy	+1,923,139	New	+$45.2M	0.45%	62

Other funds holding CTKB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MGM

Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OrbiMed's CTKB Position: Q1 2022 in Review

OrbiMed sold out of Cytek Biosciences (CTKB) in Q1 2022, closing a stake of 1,923,139 shares — an estimated $31.4M sold.

OrbiMed first reported a position in CTKB in Q3 2021 and held it in 2 quarters. The position peaked at $41.2M in Q3 2021. 74 funds tracked by Wall St. Rank hold CTKB as of Q1 2022.

OrbiMed reported no remaining Cytek Biosciences position as of Q1 2022 after selling out during the quarter.
OrbiMed sold 1,923,139 Cytek Biosciences shares in Q1 2022, an estimated $31.4M.
OrbiMed first reported a position in Cytek Biosciences in Q3 2021 and held it in 2 quarters.
OrbiMed's Cytek Biosciences position peaked at $41.2M in Q3 2021.
74 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.